Forward Ventures V, LP 13D and 13G filings for Viracta Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 8:25 pm Sale |
2024-12-31 | 13G | Viracta Therapeutics, Inc. VIRX |
Forward Ventures V, LP | 847,600 4.300% |
-1,719,922 (-66.99%) |
Filing |
| 2024-02-13 9:04 pm Sale |
2023-12-31 | 13G | Viracta Therapeutics, Inc. VIRX |
Forward Ventures V, LP | 2,567,522 6.650% |
-97,268 (-3.65%) |
Filing |
| 2022-02-09 5:24 pm Purchase |
2021-12-31 | 13G | Viracta Therapeutics, Inc. VIRX |
Forward Ventures V, LP | 2,664,790 7.140% |
42,516 (+1.62%) |
Filing |
| 2021-03-08 5:05 pm Purchase |
2021-02-25 | 13G | Viracta Therapeutics, Inc. VIRX |
Forward Ventures V, LP | 2,622,274 7.090% |
2,622,274 (New Position) |
Filing |